Join

Compare · MEDP vs MXCT

MEDP vs MXCT

Side-by-side comparison of Medpace Holdings Inc. (MEDP) and MaxCyte Inc. (MXCT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MEDP and MXCT operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
  • MEDP is the larger of the two at $13.18B, about 108.0x MXCT ($122.1M).
  • Over the past year, MEDP is up 55.3% and MXCT is down 47.4% - MEDP leads by 102.7 points.
  • MEDP has been more active in the news (4 items in the past 4 weeks vs 1 for MXCT).
  • MEDP has more recent analyst coverage (25 ratings vs 11 for MXCT).
PerformanceMEDP+55.26%MXCT-47.44%
2025-06-17+0.00%2026-06-16
MetricMEDPMXCT
Company
Medpace Holdings Inc.
MaxCyte Inc.
Price
$461.89-1.24%
$1.13-2.16%
Market cap
$13.18B
$122.1M
1M return
+11.14%
+7.62%
1Y return
+55.26%
-47.44%
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Commercial Physical & Biological Resarch
Exchange
NASDAQ
NASDAQ
IPO
2016
2021
News (4w)
4
1
Recent ratings
25
11
MEDP

Medpace Holdings Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MXCT

MaxCyte Inc.

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.